Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

MiROvaR, a microRNA-based predictor of early relapse for ovarian cancer patients

ABSTRACT: This SuperSeries is composed of the SubSeries listed below.

ORGANISM(S): Homo sapiens

PROVIDER: GSE73584 | GEO | 2016/10/31

SECONDARY ACCESSION(S): PRJNA297358

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

MiROvaR, a microRNA-based predictor of early relapse for ovarian cancer patients [validation set; OC133]

Project description:Despite a pathological complete response, risk-of-relapse remains a challenge for most of epithelial ovarian cancer (EOC) patients and an ad-hoc predictor can be a valuable clinical tool. We developed a 35 miRNAs-based predictor of Risk of Ovarian Cancer Relapse (MiROvaR) using a training set of patients from MITO-2 (Multicentre Italian Trials in Ovarian Cancer-2; Pignata S et al. J Clin Oncol. 2011 Sep 20). MiROvaR performance was confirmed in two independent validation cohorts.

2016-10-31 | GSE73582 | GEO

MiROvaR, a microRNA-based predictor of early relapse for ovarian cancer patients [training set; OC179]

2016-10-31 | GSE73581 | GEO

MiROvaR, a microRNA-based predictor of early relapse for ovarian cancer patients

Project description:MiROvaR, a microRNA-based predictor of early relapse for ovarian cancer patients

| PRJNA297358 | ENA

Identification of a chrXq27.3 microRNA cluster associated with early relapse in advanced stage ovarian cancer patients.

Project description:A major challenge in advanced-stage epithelial ovarian cancer (EOC) is prediction of chemoresistant relapse. Our aim was to identify a microRNA (miRNA) signature associated with early relapse in advanced-stage EOC patients. miRNA expression was assessed by microarray profiling in training (n = 55) and test (n = 30) sets selected on the basis of time to relapse (TTR), followed by internal quantitative reverse transcriptase-PCR validation on a set of 45 consecutive cases unselected for clinical response and external in silico validation on publicly available datasets. Thirty-two differentially expressed miRNAs in early vs. late relapsing patients were identified in the training set. In the test set, 8 of these, belonging to a cluster located on chrXq27.3, were down-modulated in early relapsing patients. Hierarchical clustering of the internal validation set according to chrXq27.3 miRNA expression associated low miRNA expression with shorter TTR (log-rank P=0.00074, HR 2.44). The cluster was an independent prognostic factor in both internal and external validation sets. Forced expression of chrXq27.3-cluster selected miRNAs in human EOC cellular models was associated to reduction of cell proliferation and increased sensitivity to cisplatin. The role of down-modulation of the chrXq27.3 miRNA cluster in early relapse of advanced-stage EOC patients and its association to a reduced sensitivity to chemotherapeutic treatments warrant further investigation.

| S-EPMC3282083 | biostudies-literature

microRNA alterations associated to early relapse in advanced stage ovarian cancer patients (validation set)

Project description:A set of 45 surgical specimens has been profiled for miRNA expression to validate miRNA alterations associated to early relapse in advanced stage ovarian cancer patients.

2015-04-30 | GSE67819 | GEO

microRNA alterations associated to early relapse in advanced stage ovarian cancer patients (validation set)

Project description:A set of 45 surgical specimens has been profiled for miRNA expression to validate miRNA alterations associated to early relapse in advanced stage ovarian cancer patients. Fresh frozen samples were collected from a series of consecutive patients with high-grade advanced stage ovarian cancer who underwent primary surgery at INT-Milan. After surgery all patients received postoperative platinum-based chemotherapy. All patients signed an Institutional Review Board approved consent for bio-banking, clinical data collection and molecular analysis. Clinical codes: Histotype: according to WHO classification guidelines Stage: according to International Federation of Gynecological and Obstetrics (FIGO) guidelines Grading: according to WHO classification guidelines Debulking: NED: not evident disease; mRD: minimal residual disease; GRD: gross residual disease Therapy code: P: Platinum without taxanes; PT: Platinum/paclitaxel

2015-04-30 | E-GEOD-67819 | biostudies-arrayexpress

microRNA alterations associated to clinical response in advanced stage ovarian cancer patients

Project description:This SuperSeries is composed of the SubSeries listed below.

2012-03-09 | GSE25204 | GEO

A circulating risk score, based on combination of exo-miR130a-3p and fibrinopeptide A, as predictive biomarker of relapse in early stage non-small cell lung cancer patients

Project description:This SuperSeries is composed of the SubSeries listed below.

2022-05-01 | GSE198959 | GEO

MicroRNA-based prognostic model for early-stage oral cancer patients

Project description:The aim of our study is to develop a miRNA marker panel prognostic of 5-year survival in early-stage OSCC patients. We assessed differential expression of miRNAs genome-wide via deep sequencing in 100 tumor tissue samples. We also attempted to identify deregulated miRNA expression signatures that may serve as the prognostic markers.

2018-07-01 | GSE107830 | GEO

microRNA Induction of Fatal Differentiation Programs is a Context-selective Vulnerability in Ovarian Cancer Cells

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2015-03-27 | E-GEOD-67330 | biostudies-arrayexpress